GSK256066 is a selective phosphodiesterase 4 (PDE4)inhibitor with an IC50 of 3.2 pM. Oral phosphodiesterase (PDE)4 inhibitors have demonstrated clinical efficacy in chronic obstructive pulmonary disease and asthma. Preclinical andclinical investigation of inhaled PDE4 inhibitors is ongoing. GSK256066 may have an improved therapeutic index compared with oral PDE4 inhibitors, e.g., cilomilast and roflumilast.GSK256066 demonstrates potent and long-lasting anti-inflammatory effects in animal models of pulmonary inflammation and does not induce emetic episodes in ferrets. GSK256066 has potential as an inhaled therapeutic for the treatment of asthma and chronic obstructive pulmonary disease.
*The compound is unstable in solutions, freshly prepared is recommended
 |
Source | J Pharmacol Exp Ther (2011). Figure 3. GSK256066 |
| Method | i.v. | |
| Cell Lines | mice | |
| Concentrations | 10 μg/kg | |
| Incubation Time | 6 h | |
| Results | GSK256066 and FP inhibited the increase in eosinophil number in the BAL in a dose-dependent fashion |
| Cell Experiment | |
|---|---|
| Cell lines | PBMCs cells line |
| Preparation method | Compound Preparation for In Vitro Assays. Dilution series for pIC50 determinations generally comprised eight successive 3-fold dilutions in DMSO. Low-volume additions (0.5-2.0 μl) to assays were carried out using a Biomek Fx liquid-handling robot (Beckman Coulter, Fullerton, CA).Percentages of inhibition values were generated relative to uninhibited controls. Values for pIC50 were determined from concentration-response curves by nonlinear least-squares curve fitting, in general using a four-parameter logistic equation in Activity Base (IDBS, Guildford, Surrey, UK). |
| Concentrations | 0~10 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | LPS-induced pulmonary neutrophilia in rats model |
| Formulation | 0.2% Tween 80 in normal saline |
| Dosages | 0.1-100 μg/kg |
| Administration | intratracheally |
| Molecular Weight | 518.58 |
| Formula | C27H26N4O5S |
| CAS Number | 801312-28-7 |
| Solubility (25°C) | DMSO 5 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related PDE Products |
|---|
| ME-3183
ME-3183 is an oral selective PDE4 inhibitor with anti-inflammatory activity for studies related to plaque psoriasis. |
| ART-648
ART-648 is a PDE4 inhibitor that may be used in studies related to non-alcoholic steatohepatitis. |
| (E/Z)-HA155
(E/Z)-HA155 is a potent Autotaxin (ATX) type I inhibitor for studies related to cancer, fibrous disorders, inflammation, pain and angiogenesis. |
| Autotaxin-IN-3
Autotaxin-IN-3 is an Autotaxin(ATX) inhibitor with an IC50 value of 2.4 nM. |
| HA155
HA155 is a potent and selective ATX inhibitor with an IC50 value of 5.7 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
